viralytics in the media, page-5

I would only expect exceptional phase 1 data from the intravenous trial (which I doubt, but expect to be similar to phase 1 intravenous, possibly less effective due to dosage) or an announcement with 5 to 10 patients accepted into the follow up trial in the near term.

Anything else will keep things similar or hopefully a gradual rise